학술논문
Safe administration of obinutuzumab to rituximab-intolerant patients.
Document Type
Letter
Author
Source
Subject
*MUCOSA-associated lymphoid tissue lymphoma
*ANTIBODY-dependent cell cytotoxicity
*TUMOR lysis syndrome
*URTICARIA
*LYMPHADENITIS
*
*
*
*
Language
ISSN
1042-8194
Abstract
Although generally well tolerated, infusion-related reactions (IRRs) occur in 30-50% of patients with indolent non-Hodgkin lymphoma (iNHL) and chronic lymphocytic leukemia (CLL), with grade 3/4 reactions in 5% [[4]]. Rituximab has been safely administered to two obinutuzumab-intolerant patients: a FL patient after a grade 4 IRR and a CLL patient with anaphylaxis [[15]]. The severity of the initial rituximab reactions compared with the absence (patients 1 and 4) or substantial reduction (patients 2 and 3) in IRR with obinutuzumab suggests that structural and functional differences between these two antibodies may lead to differing risks of reactions. Rituximab, the first anti-CD20 antibody incorporated into routine practice, is a type I chimeric murine/human antibody which predominantly acts via complement-dependent cytotoxicity (CDC), with a lesser contribution from antibody-dependent cellular cytotoxicity (ADCC) [[1]]. [Extracted from the article]